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Nanoparticles have enormous potential in diagnostic and therapeutic studies. We have demonstrated that the amyloid beta mixed
with and conjugated to dihydrolipoic acid- (DHLA) capped CdSe/ZnS quantum dots (QDs) of size approximately 2.5 nm can be
used to reduce the fibrillation process. Transmission electron microscopy (TEM) and atomic force microscopy (AFM) were used as
tools for analysis of fibrillation. There is a significant change in morphology of fibrils when amyloid β (1–42) (Aβ(1–42)) is mixed
or conjugated to the QDs. The length and the width of the fibrils vary under modified conditions. Thioflavin T (ThT) fluorescence
supports the decrease in fibril formation in presence of DHLA-capped QDs.
1. Introduction
Nanochemistry is predominating in major fields of science
and technology, specifically in biotechnology and informa-
tion technology. In the near future, nanochemistry will direct
and guide towards nanomedicine and nanodiagnostics [1].
However, obtaining suitable nanoparticles that can be used
for diagnostic and medicinal purposes remains a significant
challenge. Moreover, the eﬀect of these nanoparticles on
biological entities such as proteins is considerably significant
when it comes to AD.
Oligomeric aggregates Aβ and tau protein or the
protofibrils are considered as precursors for amyloid fib-
rillation in Alzheimer’s disease [2]. A few articles have
been published on the eﬀect of nanoparticles on fibrillation
process. Recently, the eﬀect of fluorinated magnetic core-
shell nanoparticles with the size range of 15.0 ± 2.1 nm
has been observed on amyloid model protein insulin; these
fluorinated nanoparticles show inhibition of insulin fibrils
[3, 4]. Furthermore, the eﬀect of various nanoparticles
within the dimensions of 6–200 nm on another model pro-
tein, β2 microglobulin, has been investigated [5]. Previously
published studies have demonstrated that nanoparticles can
act as catalysts for protein fibrillation [1, 5]. Very recently, Li
and coworkers have showed an inhibition eﬀect of N-acetyl
cysteine-capped CdTe QDs of size of 3–5 nm on Aβ (1–40)
fibrillation [6]. In another case, dual eﬀect of commercial
polystyrene nanoparticles with amino modification having
various sizes (57, 120, and 180 nm) was observed on Aβ (1–
40) and recombinant Aβ (1–40) and Aβ (1–42) proteins [7].
Furthermore, there is only one recent publication on the
eﬀect of nanoparticles on Aβ (1–42) fibrils. In this case, it
was observed an increase in rate of amyloid fibrillation in
presence of TiO2 nanoparticles with size of approximately
20 nm [8].
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The interaction of nanoparticles with diﬀerent proteins
depends upon various factors such as surface coating of
nanoparticles with ligands, surface properties, size, and
composition of nanoparticles [1, 5]. From the previous
studies, [1, 3–8] we cannot generalize the concept that
diﬀerent nanoparticles can promote or inhibit the fibril
formation for various amyloid model proteins. Specifically,
the only investigation that explains the eﬀect of TiO2 on
Aβ (1–42) shows that nanoparticles promote the fibrillation
process by becoming nucleation centers [8].
We report for the first time in our knowledge that
CdSe/ZnS QDs of size of 2.5 ± 1.3 nm can inhibit fibrillation
of Aβ (1–42). In the present study, we have investigated the
eﬀect of the presence of DHLA-capped CdSe/ZnS QDs either
mixed with or conjugated to Aβ (1–42) on fibrillation process
of Aβ (1–42) in aqueous phase. TEM and AFM studies show
that the QDs behave uniquely when they are conjugated to
Aβ (1–42) in comparison to a mixed sample of Aβ (1–42)
and QDs. Our study illustrates a considerable diﬀerence in
morphology of the fibrils and the inhibition of fibrillation
process when Aβ (1–42) is conjugated to QDs versus the
mixed system Aβ (1–42) and QDs. These results are further
supported by Thioflavin T (ThT) assay using fluorescence
spectroscopy.
2. Experimental Section
2.1. Materials and Methods. All Chemicals were commer-
cially purchased and used without further purification.
Cadmium oxide (CdO), selenium (Se), trioctylphosphine
oxide (TOPO), trioctylphosphine (TOP), and hexamethyl-
disilathiane [(TMS)2S] were purchased from Sigma-Aldrich
(Milwaukee, WI). The tetradecylphosphonic acid (TDPA)
was obtained from Alfa Aesar (Ward Hill, MA). The diethylz-
inc (ZnEt2, 15 wt% solution in hexane) was obtained from
Acros Organics (MorrisPlains, New Jersey). DL-α-lipoic acid,
Aβ (1–42), and ThT were purchased from MP Biomedicals
(Solon, OH).
2.2. Synthesis of DHLA-Capped QDs. CdSe/ZnS QDs were
synthesized using an already given protocol [9]. Briefly,
cadmium oxide was reacted with a selenium reagent in the
presence of a phosphine oxide surfactant at high temperature
under argon flow. After the formation of the CdSe core, the
diethyl zinc and hexamethyldisilathiane in TOP was added
dropwise at 130◦C. After the synthesis of TOPO-capped
hydrophobic QDs, modification to hydrophilic DHLA-
capped QDs was carried out [10]. Briefly, first DL-α-lipoic
acid (1 g) was reduced using sodium borohydride (2 g) in
methanol/water (v/v, 1:1) solution. After workup product
was isolated in chloroform and characterized using 1H NMR
(400 MHz, CDCl3): δ (ppm) 1.3 (d, 1H), 1.35 (t, 1H), 1.4–
1.8 (m, 6H), 1.9 (m, 2H), 2.4 (t, 2H), 2.6–2.8 (m, 2H), 2.9
(m, 1H), and 11 (s, 1H).
DHLA was used for ligand exchange with TOPO; excess
of DHLA (0.5 g) was added in 5 mL of TOPO-capped
QDs in methanol and heated at 60◦C–70◦C for 4 h. Once
a homogeneous QDs solution was obtained, solution was
basified using potassium tert-butoxide and centrifuged to get
the precipitates. The precipitates were suspended in water
to obtain the hydrophilic QDs. The water-soluble QDs were
filtered through 0.2 μm filter to get a clear solution.
2.3. Preparation of Aβ (1–42) Mixed and Conjugated with
DHLA-Capped QDs. Aβ (1–42) was chemically conjugated
to QDs by the formation of an amide bond between
Asp-NH2 end of the polypeptide chain and the –COOH
end of the DHLA ligand using the protocol to conjugate
proteins [11]. Freshly prepared DHLA-capped QDs (1.51
× 10−5 M, 100 μL) were taken in a clean borosilicate glass
vial, and 500 μL PBS buﬀer (pH 7.4) was added to the
QDs. To lyophilize the peptide, 0.5 mg Aβ (1–42) was
dissolved in hexafluoroisopropanol (HFIP) to bring the
peptide in monomer form and evaporated under gentle flow
of N2. The dried protein was then dissolved in 500 μL PBS
buﬀer (pH 7.4) to get the final concentration of 1 mg/mL.
Freshly prepared Aβ (1–42) solution was then mixed in
QDs solution. 57 μL of freshly prepared 10 mg/mL EDC (1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride) solution in deionized water was then added to the
mixture of peptide and QDs, total volume of solution
prepared was 1157 μL. The solution was stirred for 4 h at the
speed of 200 rpm. There was no precipitate observed after
the reaction. Aβ (1–42) mixed with DHLA-capped QDs was
prepared according to the above-mentioned protocol except
for the addition of EDC. Total volume of the solution was
kept at 1157 μL. For the induction of fibrillation the solutions
were incubated at 37◦C.
2.4. Preparation of Pure Aβ (1–42) Sample for Fibrillation.
Pure Aβ (1–42) solution was prepared similarly, first by
lyophilizing the peptide in HFIP and evaporating the solvent
under gentle nitrogen flow and then redissolving the dried
peptide in 1157 μL of PBS buﬀer (pH 7.4). The solution was
then incubated at 37◦C to induce the fibril formation.
2.5. Gel Electrophoresis. Electrophoresis of QDs was per-
formed using a MiniCuve 8.10 Electrophoresis Unit (MP
Biomedicals, Solon, OH). Hand cast gels were composed of
1% agarose in 1×TBE (0.089 M Tris base, 0.089 M boric acid,
and 0.002 M ethylenediaminetetraaceticacid, pH 8.3). 10 μL
of each sample was loaded into wells on the agarose gel using
a micropipet. The samples were run in 1× TBE buﬀer on
the 1% agarose gel at 84 V for 75 min. For visualization, the
gel was placed on a UV transilluminator, and an image was
captured with a Gel Doc XR system (Bio-Rad, Hercules, CA).
2.6. TEM Measurements. TEM measurements were per-
formed at the Center of Advanced Microscopy, Scripps
Research Institute (La Jolla, CA) and at the Center of
Advanced Microscopy, (CMA), Trinity College Dublin (Ire-
land). For the images containing amyloid, negative staining
was performed using 2% uranyl acetate. Briefly, copper grids
(carbon and Formvar coated 400 mesh: Electron Microscopy
Sciences, Hatfield, PA) were glow discharged and inverted
on an 5 μL aliquot of sample for 3 min. Excess sample
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Figure 1: (a) Absorption and emission spectra of DHLA-capped QDs. Fluorescence spectrum was obtained using a quartz cell with an
optical path length of 1 cm, excitation wavelength at 467 nm, and 2, 2 nm slit width at the excitation and emission, respectively; (b) UV-vis
and fluorescence spectra for fluorescein; (c) DHLA-capped QDs used for quantum yield measurements.
was removed and the grids immediately placed briefly on
a droplet of double-distilled water. Grids requiring the
negative stain were then placed on droplets of 2% uranyl
acetate solution for 2 min. Excess stain was removed and the
grid was allowed to dry thoroughly. For unstained grids, the
excess water was removed, and the dried grids were examined
on a Philips CM100 electron microscope (FEI, Hillsbrough,
OR) at 80 kV and images collected using a Megaview III
CCD camera (Olympus Soft Imaging Solutions, Lakewood,
CO). Grids at Ireland were examined on a Jeol 2100 electron
microscope (Zeiss) operating at 200 kV and images collected
using a CCD camera. Analysis of TEM images was performed
using Image J software from NIH (http://rsbweb.nih.gov/ij/).
2.7. AFM Measurements. Briefly, 4 μL aliquots of Aβ solu-
tions were deposited on freshly cleaned and dried silicon
wafers (approximately 1 mm thick). After waiting for 10
min, nonadsorbed portions of the samples were washed
with deionized water (400 μL). The wet surface of the
silicon wafer was then dried using gentle flow of air. The
samples were analyzed by atomic force microscopy (AFM, βA
multimode SPM, Model no. 920-006-101, Veeco, Fremont,
CA). Tapping mode approach was used to acquire the images,
which allows intermittent contact of the tip with the sample
and minimizes the chances of deformation of the peptide
samples. The cantilever and the tip were made up of silicon.
The cantilever force constant was approximately 20–100 N/m
with the resonance frequency between 200 and 400 kHz. The
scan rate was between 1.0 and 1.2 Hz. The software used for
the analysis of fibrils was the NanoScope Control, version
5.30 and the histogram analysis was performed using the
postanalysis pico image software (pico view version 1.6.2).
2.8. UV-Vis and Fluorescence Spectroscopy. UV-vis spectra
of solutions were recorded on a Perkin-Elmer Lambda
900 UV/vis/NIR spectrometer (Norwalk, CT). Fluorescence
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Figure 2: (a) UV-vis and fluorescence spectra of Aβ (1–42). Fluorescence spectrum was obtained using a quartz cell with an optical
path length of 1 cm, excitation wavelength at 280 nm, and 5, 5 nm slit width at the excitation and emission, respectively; (b) UV-vis and
fluorescence spectra for Aβ (1–42) mixed (—) and conjugated ( ) to QDs. Fluorescence spectrum was obtained using a quartz cell with
an optical path length of 1 cm, excitation wavelength at 467 nm, and 2, 2 nm slit width at the excitation and emission, respectively.
spectra were obtained using Spex FluoroLog Fluorospec-
trometer (Horiba Jobin Yvon, Edison, NJ). Both UV-vis
and fluorescence measurements were obtained using quartz
cuvette with1 cm optical path length.
2.9. ThT Fluorescence. 10 μM solution of ThT was prepared
in 1xPBS buﬀer at pH 7.4. 30 μL of Aβ (1–42) aliquots
were extracted at diﬀerent time periods, and 300 μL of ThT
(10 μM) was added to the samples. The ThT fluorescence was
measured at 482 nm at an excitation wavelength of 440 nm in
a semimicro quartz cuvette of an optical pathlength of 1 cm.
Slit widths at excitation and emission were set at 5 nm.
3. Results and Discussion
3.1. Characterization of QDs and QDs Mixed and Conjugated
with Aβ (1–42). Characterization of DHLA-capped QDs
was carried out using UV-vis and fluorescence spectroscopy
(Figure 1(a)). Quantum yield (QY) has been calculated for
the QDs investigated. The fluorescein (QY is 0.94 in 0.1 M
NaOH) was employed as reference. The QY was calculated
by using the following equation:
QYq =
QY f
[
Af n2q
∫
Iq(λ)dλ
]
[
Aqn
2
f
∫
I f (λ)dλ
] . (1)
A is the absorbance at the excitation wavelength, n is
the refractive index of the solvent used, I is the emission
wavelength-dependent emission intensity, and λ is the
emission wavelength. Subscripts q and f represent the QDs
and the fluorescein, respectively. QY was calculated from the
intensity of luminescence and the absorbance in Figures 1(b)
and 1(c) for fluorescein (0.1 M NaOH as solvent) and QDs
(water as solvent), respectively. The QY of the DHLA-capped
CdSe/ZnS QDs was around 25%.
3.1.1. Estimation of Aβ/QDs Ratio. To characterize the QDs
conjugated to Aβ (1–42), it is important to estimate the
number of Aβ monomers bound to QDs after conjugation.
Firstly, characterization of samples of pure Aβ (1–42), Aβ (1–
42) mixed and conjugated to QDs was performed using UV-
vis and fluorescence spectroscopy (Figure 2). The emission
band for the tyrosine moiety in Aβ (1–42) was observed at
309 nm at the excitation wavelength of 280 nm, slit width
at emission and excitation was set at 5 nm. The absorption
band for Aβ (1–42) was observed at 275 nm (Figure 2(a)),
whereas the emission band for the Aβ (1–42) mixed and
conjugated to QDs was observed at 560 nm at the excitation
wavelength of 467 nm. The absorption band for the QDs
was observed at 547 nm and for the Aβ (1–42) a little hump
was observed at 275 nm as shown in Figure 2(b). Molar
concentration of the QDs and Aβ (1–42) was calculated
from UV-vis spectrum of the solution [12, 13], the optical
path length used was 1 cm. The ratio of these concentration
values gave the average number of Aβ per quantum dot
nanoparticles. The molar extinction coeﬃcient of QDs at
547 nm is 105.8 × 103 M−1 cm−1 and at 275 nm is 2.6 ×
103 M−1 cm−1. Extinction coeﬃcient for Aβ (1–42) [14] at
275 nm is 1.4× 103 M−1 cm−1. The calculations to determine
the ratio of Aβ (1–42) and QDs are shown below.
International Journal of Alzheimer’s Disease 5
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Figure 3: Gel electrophoresis image of DHLA-capped QDs (1)
in comparison to DHLA-capped QDs mixed (3) and conjugated
(5) to Aβ (1–42). PEG-capped QDs (2) in comparison to PEG-
capped mixed (4) and conjugated (6) to Aβ (1–42). The purified
fractions using gel chromatography for DHLA- and PEG-capped
QDs conjugated to Aβ (1–42) are shown in wells 7 and 8,
respectively.
3.1.2. AβConjugated to DHLA-CappedQDs. QDs concentra-
tion (conjugated sample) is
Abs547
ε547l
= 0.156
1.05 × 105 M−1 cm−1 × 1 cm = 1.5× 10
−6 M.
(2)
Absorption at 275 nm from QDs is
Abs547 × ε275
ε547
= 0.156× 2637.2
1.05× 105 = 3.9× 10
−3 . (3)
Absorption at 275 nm from Aβ (1–42) is
Abs275 −
[
Abs547 × ε275
ε547
]
= 2.2− 3.9 × 10−3 = 2.2. (4)
Aβ (1–42) concentration in the sample conjugated to QDs is
Abs for Aβ at 275
ε for Aβ at 275× l =
2.2
1390 M−1cm−1 × 1 cm
= 1.6× 10−3 M,
Loading = Aβ concentration
QDs concentration
= 1.6× 10
−3 M
1.5× 10−6 M
= 1.1× 103.
(5)
Theoretically, the total number of molecules/particle of Aβ
(1–42) (molecular weight 4514.1 g) present in 0.5 mg of
the 1157 μL of sample can be calculated by multiplying the
number of moles with NA (Avogadro’s number) number of
molecules. Hence, the total number of molecules of Aβ (1–
42) present in the sample is 5.8 ×1021. Similarly, the total
number of QDs particles present in the solution is 9.0 ×1017.
Therefore, the ratio of Aβ (1–42) molecules per QD particle
is 6400. Subtracting the experimental value (1100) from the
theoretical value (6400), it can be inferred that there are 5300
molecules of Aβ (1–42) that are free in the solution per QD
particle that is conjugated to Aβ (1–42).
3.1.3. Gel Electrophoresis. To confirm that the QDs were
indeed conjugated to Aβ (1–42), we have used the agarose
gel electrophoresis for the control DHLA-capped CdSe/ZnS
QDs along with Aβ (1–42) mixed and conjugated to the
QDs (Figure 3). The gel was run in TAE buﬀer (pH 7.4)
at 84 V for 75 min, and the volume of the samples in each
well was 10 μL. Figure 3 shows the distance moved by three
diﬀerent samples: DHLA-capped QDs (1), Aβ (1–42) mixed
with DHLA-capped QDs (3), and Aβ (1–42) conjugated with
DHLA-capped QDs (5). From the gel electrophoresis, we can
clearly distinguish that the distance moved by the QDs mixed
with Aβ (1–42) is the same as for the pure DHLA-capped
QDs. Whereas when the QDs are conjugated to Aβ (1–42),
the distance moved is lower. This shows that when the QDs
are chemically conjugated to Aβ (1–42), the distance moved
is reduced due to the higher molecular weight. Moreover,
comparison of polyethylene glycol (PEG)-capped QDs (2),
Aβ (1–42) mixed PEG-capped QDs (4), and Aβ (1–42)
conjugated PEG-capped QDs (6) shows that PEG-capped
QDs when conjugated travel the least distance. Purified
fractions of DHLA- (7) and PEG-capped (8) QDs conjugated
to peptide show that free Aβ (1–42) can be separated from
the Aβ (1–42) conjugated QDs. Diﬀerent fractions of 1 mL
each obtained from gel chromatography were checked for
the presence of free Aβ (1–42) using UV-vis absorption and
fluorescence spectroscopy.
4. Imaging and Analysis
4.1. TEM. First evidence on the inhibition in fibrillation
comes from TEM images (Figure 4) taken on the 7th day
of incubation at 37◦C. TEM images containing Aβ (1–42)
are negatively stained using 2% uranyl acetate solution.
Three diﬀerent samples, namely, pure Aβ (1–42), Aβ (1–
42) mixed with DHLA-capped CdSe/ZnS QDs, and Aβ (1–
42) conjugated to DHLA-capped CdSe/ZnS QDs, are shown
in Figures 4(a), 4(c), and 4(d), respectively. In all the three
samples, the concentration of Aβ (1–42) is 0.96× 10−4 M and
the concentration of QDs is 1.4 μM. Figure 4(a) shows a TEM
image of pure Aβ (1–42). Analysis of this image indicates
that the length of the fibrils varies from 30 to 1730 nm. The
width of the shorter fibrils is 4.0 ± 0.7 nm whereas for the
longer fibrils it is 7.5 ± 0.5 nm. Figure 4(b) presents the pure
DHLA-capped CdSe/ZnS QDs, the average particle size is
2.5 ± 1.3 nm (Figure 5(a)). The size of QDs is an important
parameter for the biodiagnostic studies, since smaller size
QDs are capable of passing through the blood-brain barrier
6 International Journal of Alzheimer’s Disease
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Figure 4: TEM images: (a) Aβ (1–42) in PBS buﬀer (pH 7.4); (b) DHLA-capped QDs; (c) Aβ (1–42) mixed with DHLA-capped QDs in PBS
buﬀer (pH 7.4); (d) Aβ (1–42) conjugated to DHLA-capped QDs in PBS buﬀer (pH 7.4).
[15, 16]. Figure 4(c) shows the incubated sample of Aβ (1–
42) in the presence of QDs whereas Figure 4(d) shows Aβ
(1–42) conjugated QDs. Comparison of the results in the
three images containing Aβ (1–42) illustrates very interesting
pattern. Sample containing pure Aβ (1–42), Figure 4(a), has
a large number of fibrils ranging from short fibrils around
30 nm to long fibrils around 2 micron whereas images of
samples in presence of QDs are very diﬀerent. Figure 4(c) is
the image of Aβ (1–42) mixed with QDs; it shows long-length
fibrils of around 1 micron. The short-length fibrils are not
very significant in this case. The width of the fibrils for the
sample having mixed QDs is 7.7± 0.7 nm. Figure 4(d) for Aβ
(1–42) conjugated to QDs shows short-length fibrils ranging
from 30 to 80 nm. For this sample, the thickness or width
of the fibrils is 10 ± 3 nm. The variation in the thickness of
fibrils is significant in this case as compared to the other two.
One can see a distinguishable inhibition of the fibrillation
when Aβ (1–42) is conjugated to QDs.
Histogram showing the size of DHLA-capped QDs is
shown in Figure 5(a). The average size analyzed from the
histogram obtained from TEM images is 2.5 ± 1.3 nm.
Furthermore, to consolidate the results, we have performed
the statistical analysis on the TEM images (13–18 images
per sample). The number of short-length fibrils (80–150 nm)
observed in the sample containing pure Aβ (1–42) was
extremely high as compared to samples containing QDs.
Statistical analysis showed (Figure 5(b)) that the number of
fibrils having length 50–100 nm dropped to 90% in the case
of Aβ (1–42) mixed to QDs. There were only 26% of short-
length fibrils observed for Aβ (1–42) conjugated to QDs.
The total number of fibrils in the samples containing QDs
mixed or conjugated to Aβ (1–42) was similar (35 fibrils
approximately). These results confirm that elongation of
fibrils is inhibited by the presence of the QDs. Figures 6(a)
and 6(b) show the TEM images of unstained samples of
Aβ (1–42) mixed with QDs. Contrary to the TEM images
of stained samples where we can observe only fibrils and
no QDs, in this case, we were able to observe the QDs, as
well as fibrils. It could be discerned from the results that
QDs are enveloping the fibrils and more number of QDs are
observed at the ends of the fibrils. For the samples containing
Aβ (1–42) conjugated to QDs (Figures 6(c) and 6(d)), we
could observe less number of QDs and short-length fibrils.
The QDs observed in this case are segregated at one end of
the fibrils as seen in Figure 6(d). It could be infered from
the results obtained using unstained samples (Figure 6) that
QDs envelop the fibrils and could block the ends to elongate.
Importance of the C terminus of the Aβ (1–42) in controlling
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Figure 5: (a) Histogram for the size distribution of DHLA-capped CdSe/ZnS QDs; (b) statistical analysis of number of fibrils versus length
of fibrils for three diﬀerent samples containing Aβ (1–42) mixed to DHLA-capped QDs, Aβ (1–42) conjugated to DHLA-capped QDs, and
pure Aβ (1–42).
the self-assembly of fibrillation was revealed before [17]. The
reason for the inhibition of fibrillation in presence of QDs
could be that the small size of particles could block the
C-terminal end of the fibrils (∼10 nm) or the protofibrils
(∼5 nm in diameter), which is considered as the terminus
with lower degree of freedom and accessibility for elongation
mechanism [18]. Furthermore, binding between the QDs
and the Aβ (1–42) could block the active sites leading to low
local protein concentration, hence increasing the lag time for
nucleation or disrupting the nucleation process leading to
inhibition of the fibrillation process [19]. Besides, presence
of Aβ (1–42) conjugated to QDs in the sample containing
free Aβ (1–42) may perturb the nucleation mechanism with
decrease in localised concentration of the Aβ (1–42) as
thereby inhibiting fibrillation process [19, 20]. However,
mixed sample of Aβ (1–42) and the QDs might increase
the localised concentration of the polypeptide, thereby
increasing the length of fibrils but the number of fibrils still
remains low suggesting that there is a perturbation in the
mechanism of the fibrillation process [20].
4.2. AFM. The TEM results are supported by the AFM
images as shown in Figure 7 for the 7th day of incubation
at 37◦C. Analysis of AFM image for Aβ (1–42) in absence of
QDs (Figure 7(a)) shows that the length of the longest fibril
is 523 nm and the shortest fibril is 30 nm. A bigger number of
short length fibrils (30–80 nm) are observed as witnessed by
the TEM images whereas in the sample containing Aβ (1–42)
mixed to QDs (Figure 7(c)) the length of the longest fibrils
is 849 nm, comparable to the length of fibrils (1 μm) found
in the TEM images. However, when we compare the length
of fibrils (Figure 7(d)) in the sample containing Aβ (1–42)
conjugated to QDs, very few long fibrils were observed,
which correspond to the TEM images of the same sample.
The length of the longest fibrils found is 468 nm and the
shortest fibril is 58 nm, while in the case of the TEM images
the length of fibrils is between 30 and 80 nm. The height
analysis of QDs (Figure 7(b)) shows that the root mean
square height of QDs is 2.3 nm, which is comparable to the
average height of QDs found in TEM images (2.5 ± 1.3 nm).
The measurement of Z-height of the Aβ aggregates shows
that when Aβ (1–42) is conjugated to QDs the height
distribution histogram changes significantly. It is known for
the Aβ oligomers that the average height is between 3 and
5 nm, and for the fibrils it varies from 3 to 9 nm [21, 22].
From the height distribution curves (Figure 8) one can see
that in the case of amyloid fibrils in absence of QDs 40%
of aggregates have height greater than 8 nm whereas 60% of
aggregates have height between 6 and 8 nm. For the sample
of Aβ (1–42) mixed with QDs, 30% of the aggregates have
height greater than 7 nm, and 70% of the aggregates have
height between 1 and 3 nm. Interestingly, when we analyze
the height distribution for Aβ (1–42) conjugated to QDs only
14% of the aggregates have height greater than 7 nm. Almost
90% of the aggregates have height between 2 and 4 nm.
To further examine the fibrillation process and to support
the image analysis, we have performed the ThT assay
for the three incubated samples. It is known that the
fluorescence intensity of the ThT dye grows with increasing
concentration of fibrils. It has to be pointed out that previous
8 International Journal of Alzheimer’s Disease
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Figure 6: TEM images of the unstained samples of Aβ (1–42) mixed to DHLA-capped QDs (a), (b) and Aβ (1–42) conjugated to DHLA-
capped QDs (c), (d).
studies confirmed that the fluorescence enhancement of ThT
depends upon the structure of the aggregated state of the
amyloid peptides [23, 24]. Figure 9(a) shows the ThT assay
on the 7th day for the samples incubated at 37◦C. When
the pure solution of 10 μM ThT in PBS buﬀer (pH 7.4) is
excited at 440 nm, the emission band at 482 nm is observed
with a very low intensity. In the presence of amyloid fibrils,
the ThT emission band at 482 nm is enhanced significantly.
For the sample containing QDs mixed to the fibrils, the
intensity of the emission band at 482 nm is decreased by
66% as compared to the band for pure amyloid fibrils.
Whereas the amyloid fibrils, conjugated to QDs show a
decrease in intensity for the emission band by 40% as
compared to the QDs mixed to the fibrils. Time course of
fibrillation process using ThT can be seen in Figure 9(b).
The variation of ThT intensity yields information regarding
the extent of fibrillation. For the sample containing pure
Aβ (1–42), a sigmoidal curve is observed, lag phase is
between 0 and 24 h, and rapid progress in fibrillation is
observed after 50 h of incubation. However, for the sample
containing DHLA-capped QDs mixed to Aβ (1–42), lag time
is increased to 48 h and it can be observed with decrease
in intensity of fluorescence that the QDs are inhibiting the
fibril formation. Similarly, in the case of sample containing
Aβ (1–42) conjugated to the DHLA-capped QDs, a decrease
in intensity of fluorescence and completion of saturation
in fibrillation are observed at 72 h. These results show, in
the presence of QDs, that the self-assembly of Aβ (1–42) is
perturbed.
A remarkable diminution in fibrillation process in the
presence of QDs and a significant change in morphology are
observed. Contrary to the results that have been published
previously on the nanoparticles such as TiO2, copolymer par-
ticles, cerium oxide, QDs, and carbon nanotubes behaving as
catalyst for fibrillation [5, 8], we did not observe the same
behavior for the DHLA-capped CdSe/ZnS QDs. Moreover,
our results are in line with a very recent publication showing
the inhibition of Aβ (1–40) by CdTe nanoparticles which
have similar diameter size (3–5 nm) [6]. Major diﬀerence
from other set of nanoparticles being used could be the
composition and the size of the particles. The size range for
the particles that have been used for the previous studies
varies from 16 to 200 nm whereas the QDs used in our work
have an average size of 2.5 ± 1.3 nm.
To investigate the eﬀect on the tyrosine residue, which
is an intrinsic probe of Aβ (1–42), we have examined the
tyrosine fluorescence spectra for the three samples on the
7th day of incubation at 37◦C. There is a notable quenching
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Figure 7: AFM images: (a) Aβ (1–42) in PBS buﬀer (pH 7.4), 8 μm× 8 μm; (b) DHLA-capped QDs, 1 μm× 1 μm; (c) Aβ (1–42) mixed with
DHLA-capped QDs in PBS buﬀer (pH 7.4), 4 μm × 4 μm; (d) Aβ (1–42) conjugated to DHLA-capped QDs in PBS buﬀer (pH 7.4), 4 μm ×
4 μm.
of the tyrosine fluorescence intensity at 309 nm (Figure 9(c))
in the presence of mixed or conjugated QDs. This eﬀect
could be due to the fact that the tyrosine moiety (Tyr10)
interacts with the QDs. For example, the three histidine
residues (His6, His13, and His14) in the vicinity of the tyrosine
may interact or form coordination bond with the surface of
QDs [25]. This phenomenon happens due to the presence of
overcoated ZnS shell oﬀering Zn ions [26], hence rendering
tyrosine to interact with QDs and consequently decreasing
significantly the fluorescence intensity of tyrosine band.
Another explanation could be the FRET mechanism between
the donor (tyrosine moiety) and the acceptor (QDs), since
there is an overlap between the absorption spectrum of the
acceptor (QDs) and the emission spectrum of the donor
(tyrosine). FRET eﬃciency in case of Aβ (1–42) conjugated
to QDs was 0.84 whereas for Aβ (1–42) mixed with QDs was
0.94. It could be interpreted that the Forster distance (Ro)
between the Aβ (1–42) and QDs in aqueous solution was less
than 60 A˚ which is the critical distance for energy transfer
[27]. It means that in both the samples, Aβ (1–42) mixed
with or conjugated to QDs, Aβ (1–42) is present very near to
the QDs. This is an indirect evidence that QDs are present
very near to fibrils; that is also observed in the TEM images
of the unstained samples (Figure 6).
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Figure 8: Histogram representing height of fibrils or particles versus percentage of fibrils or particles for (a) pure Aβ (1–42), (b) DHLA-
capped QDs, (c) Aβ (1–42) mixed with DHLA-capped QDs, and (d) Aβ (1–42) conjugated to DHLA-capped QDs.
Furthermore, to examine the inhibition eﬀect of CdSe/
ZnS QDs, we performed the same set of experiments using
polyethylene glycol (PEG) (MW 400)-capped CdSe/ZnS
QDs. No inhibition on fibrillation process is observed
when PEG-capped QDs are mixed or conjugated to Aβ
(1–42). Figures 10(a) and 10(b) show the AFM images
of PEG-capped QDs conjugated and mixed to Aβ (1–
42), respectively, after 2 days. The length of the fibrils is
between 700 nm and 3 μm and the height of oligomers is
observed between 2.5 and 5.9 nm. Increase in intensity of
fluorescence at 482 nm for the PEG-capped QDs mixed or
conjugated with Aβ (1–42) shows that there is increase in
fibrillation in presence of PEG-capped QDs. Experiments
were also designed where DHLA- or PEG-capped QDs were
purified using gel chromatography to check the inhibition
eﬀect. Similar results are obtained over a period of 72 h
with the purified fractions of DHLA-or PEG-capped QDs,
that is, inhibition and absence of inhibition on fibrillation
process, respectively. It shows that if we change the ligand
of the QDs, it changes its behavior towards the fibrillation
process. The emission band for the PEG-capped QDs was
observed at 472 nm, when the excitation wavelength was
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Figure 9: (a) ThT fluorescence after 7 days of incubation at 37◦C for Aβ (1–42) (); ThT assay after 7 days of incubation at 37◦C for Aβ
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12 International Journal of Alzheimer’s Disease
0 2
(μm)
6 8
0
2
4
6
8
4
(a)
0 1 2 3 4
(μm)
0
1
2
3
4
(b)
440 460 480 500
Wavelength (nm)
520
PEG QDs mixed to Aβ (1–42) day1
PEG QDs mixed to Aβ (1–42) day2
PEG QDs conjugated to Aβ (1–42) day1
PEG QDs conjugated to Aβ (1–42) day2
Aβ (1–42) fibrils day2
Aβ (1–42) fibrils day1
540 560
1
2
3
4I
n
te
n
si
ty
of
fl
u
or
es
en
ce
5
6
7
8
9
10
11
12
13
×105
(c)
Figure 10: AFM image of (a) PEG-capped QDs conjugated with Aβ (1–42) in PBS buﬀer (pH 7.4), 8 μm × 8 μm; (b) PEG-capped QDs
mixed with Aβ (1–42) in PBS buﬀer (pH 7.4), 4 μm × 4 μm; (c) comparison of ThT fluorescence for 2 days for PEG-capped QDs mixed and
conjugated with Aβ (1–42) and pure Aβ (1–42) fibrils.
set at 467 nm. The absorption maxima was observed at
456 nm. The average size for the PEG-capped QDs obtained
using TEM analysis was 19.4 ± 4.7 nm (Figure 10). This
change in behavior might be due to the fact that PEG-
capped QDs tend to aggregate in buﬀer solutions, and PEG
polymer increases the size of the QDs [28]. These two
factors make the QDs nanoparticles less dynamic in solution
and less accessible for the Aβ (1–42) monomers, where
the nanoparticles can block the active sites for extended
fibrillation.
Figures 11(a) and 11(b) show the TEM images of PEG-
capped QDs. The average size for the PEG-capped QDs
obtained using TEM analysis was 19.4± 4.7 nm as illustrated
in the histogram (Figure 11(c)).
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Figure 12: Diminution of fibrillation process in presence of DHLA-
capped QDs.
5. Conclusion
QDs mixed or conjugated to Aβ (1–42) show a decrease
in the fibrillation as compared to pure Aβ (1–42), when
incubated at 37◦C for 7 days. TEM images show diﬀerence
in morphology and length of the fibrils. Longer fibrils (2
micron) are observed in the sample containing Aβ (1–42)
mixed with QDs. Pure Aβ (1–42) sample contained large
number of short- and long-length fibrils (30–1730 nm).
Thicker and shortest length fibrils (30–80 nm) are observed
in the case of Aβ (1–42) conjugated to QDs. The height
analysis of AFM images shows significant decrease in height
of aggregates greater than 7 nm (only 14%) when QDs are
conjugated to Aβ (1–42) and 30% when QDs are mixed to Aβ
(1–42) as compared to pure Aβ (1–42) solution. ThT assay
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for the samples confirmed the inhibition of the fibrillation
process when Aβ (1–42) is mixed or conjugated to QDs.
Moreover, quenching of tyrosine signal is observed in the
presence of QDs, which indicates an interaction of the QDs
with the Tyr residue in Aβ (1–42). However, in presence
of PEG-capped QDs mixed or conjugated to Aβ (1–42), an
absence of inhibition on fibrillation is observed as revealed
by AFM images and ThT fluorescence. The conclusion of
this work is presented in Figure 12 that shows diminution in
fibrillation in presence of DHLA-capped QDs, either mixed
with or conjugated to Aβ (1–42).
To investigate the use of QDs in vivo studies is very
important part of biomedical applications, there is a recent
investigation showing the use of QDs for imaging and
delivery purposes, where QDs carrying SNARE-tagged Rbd
were delivered at the synaptic contacts in the cultures from
hippocampal neurons obtained from mice [29]. Moreover,
QDs doped with SiO2 nanoparticles showed imaging and
gene carrier capabilities, it was demonstrated that these QDs
were internalized by primary cortical neural cells without
inducing cell death in vitro and in vivo [30]. Point to be noted
is CdSe quantum dots are toxic and might not be used for
medicinal purposes. However, some toxicology studies have
shown that the toxicity of QDs is size and concentration
dependent [19]. For example, cytotoxicity studies of CdSe
QDs on B16 F10 melanoma cells, and C57/BL6 mice showed
no detectable toxicity [31]. Early studies have shown high
toxicity of CdSe QDs due to the release of toxic Cd2+ ions
[32]; however, coating of ZnS has shown to reduce the
toxicity in cell culture to a great extent [33]. Nevertheless,
extensive studies are required in the field of toxicology. In the
light of these studies, it would be important to test Aβ (1–
42) mixed with or conjugated to QDs in the cultures from
neurons of mice to investigate the eﬀect of QDs in in vivo
systems.
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